Press Releases

Date Title  
Toggle Summary Aimmune to Present at RBC Capital Markets Global Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt , will present at the RBC Capital Markets Global
Toggle Summary Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
- Company Enters into Commercial Supply Agreement for AR101 - BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S.
Toggle Summary Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights
Potential FDA approval of AR101 for peanut allergy expected by late January 2020 ; Company on target to be launch-ready in Q4 2019 Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial Initiation of AR201
Toggle Summary Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
BRISBANE, Calif. --(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019 , at 4:30 p.m.
Toggle Summary Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., President and Chief Executive Officer, will present at the Needham &
Toggle Summary European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
-- Company Intends to Submit European MAA in Mid-2019 -- -- Webcast and Conference Call Today at 8:30 a.m. EDT -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies,
Toggle Summary U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the
Toggle Summary Aimmune Therapeutics to Participate in Three Investor Conferences in March
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights
FDA decision on AR101 BLA filing acceptance expected by end of March Submission of AR101 marketing application in Europe on track for mid-2019 Initiation of AR201 phase 2 trial in egg allergy on track for mid-2019 Company began 2019 with approximately $340 million in cash and investments and
Toggle Summary Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment
— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE — — AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit